Alumis (NASDAQ:ALMS - Get Free Report) is projected to announce its earnings results before the market opens on Wednesday, February 12th. Analysts expect the company to announce earnings of ($1.36) per share for the quarter.
Alumis Stock Down 14.0 %
Shares of NASDAQ:ALMS traded down $0.92 on Friday, hitting $5.67. The stock had a trading volume of 1,466,875 shares, compared to its average volume of 170,377. The firm's 50 day moving average price is $7.80 and its 200-day moving average price is $10.22. Alumis has a twelve month low of $4.86 and a twelve month high of $13.53.
Analysts Set New Price Targets
A number of research analysts have recently issued reports on the stock. Cantor Fitzgerald reiterated an "overweight" rating on shares of Alumis in a research note on Thursday, November 14th. HC Wainwright lowered their target price on Alumis from $26.00 to $19.00 and set a "buy" rating for the company in a research note on Friday. Baird R W upgraded shares of Alumis to a "strong-buy" rating in a research report on Thursday, October 31st. Robert W. Baird started coverage on shares of Alumis in a research report on Thursday, October 31st. They issued an "outperform" rating and a $25.00 price objective for the company. Finally, Oppenheimer began coverage on shares of Alumis in a research report on Thursday, January 30th. They set an "outperform" rating and a $32.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $26.57.
Read Our Latest Report on Alumis
About Alumis
(
Get Free Report)
Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.
Featured Articles
Before you consider Alumis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.
While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
